<DOC>
	<DOCNO>NCT00081978</DOCNO>
	<brief_summary>The purpose study investigate ability TMC125 , Non-Nucleoside Reverse Transcriptase Inhibitor ( NNRTI ) , low amount virus blood administer twice daily 48 week .</brief_summary>
	<brief_title>TMC125-C223 : TMC125 HIV-1 Infected Subjects</brief_title>
	<detailed_description>TMC125 give addition combination anti-HIV drug select specifically doctor . There three treatment group study . One group give dosage TMC125 , 400 mg twice daily . Another give 800 mg twice daily . The third group , control arm , receive TMC125 ( formulation TF035 ) . The safety , tolerability pharmacokinetics ( determination concentration drug blood evolution time ) TMC125 also evaluate study . Patients know resistance NNRTIs 3 protease inhibitor ( PI ) mutation may eligible participate . One-hundred-fifty ( 150 ) patient enrol study . TMC125 , 400mg twice daily 48 week ; TMC125 , 800mg twice daily 48 week .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Etravirine</mesh_term>
	<criteria>HIV1 plasma viral load screen &gt; 1000 copies/ml Documented genotypic evidence resistance currently available NNRTIs Previous NRTI experience least 3 month 3 primary PI mutation screen Chronic HBV and/or HCV elevate liver function test &gt; 3x upper normal limit Any grade 3 4 toxicity accord ACTG grade severity list ( except grade 3 glucose asymptomatic triglyceride/cholesterol grade 3 4 elevation ) Previous permanent discontinuation NNRTI due cutaneous event .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2010</verification_date>
	<keyword>HIV infection</keyword>
	<keyword>TMC125</keyword>
	<keyword>Non-nucleoside reverse transcriptase inhibitor , TMC125-C223</keyword>
</DOC>